Publication:


abstract

Current non-small cell lung cancer (NSCLC) chemotherapy and radiotherapy regimens, although showing definite survival benefit, still leave patients with a disappointing 15% 5-year overall survival rate. Because of the need to improve traditional outcomes, research has focused on identifying specific tumorigenic pathways that may serve as therapeutic targets. The most successful strategies to date are those aimed at the epidermal growth factor receptor (EGFR), which is found to be upregulated in 40%-80% of NSCLC. Several tyrosine kinase inhibitors and monoclonal antibodies (mAbs) have been developed that inhibit the EGFR receptor and have demonstrated clinical benefit in trials as single agents and in combination regimens. Here we discuss one such agent, the mAb nimotuzumab, the background of its development, its clinical experience in NSCLC thus far, and the rationale for expanding its use to other NSCLC treatment settings.

Related Articles
Review Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Chest. 2005
Review Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA, Rivera MP. Chest. 2005 Dec; 128(6):3975-84.
Role of tyrosine kinase inhibitors in lung cancer.
Anticancer Agents Med Chem. 2009
Role of tyrosine kinase inhibitors in lung cancer.
Ansari J, Palmer DH, Rea DW, Hussain SA. Anticancer Agents Med Chem. 2009 Jun; 9(5):569-75.
Review Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Clin Lung Cancer. 2004
Review Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Fuster LM, Sandler AB. Clin Lung Cancer. 2004 Dec; 6 Suppl 1:S24-9.
Review Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Oncology (Williston Park). 2006
Review Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE, Chu E. Oncology (Williston Park). 2006 Apr; 20(5 Suppl 2):15-25.
Review Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Oncologist. 2009
Review Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C, Maione P, Ferrara ML, Rossi A. Oncologist. 2009 Jun; 14(6):601-11. Epub 2009 May 29.